Twist Bioscience Corp·4

Mar 10, 4:05 PM ET

Leproust Emily M. 4

4 · Twist Bioscience Corp · Filed Mar 10, 2026

Research Summary

AI-generated summary of this filing

Updated

Twist Bioscience (TWST) CEO Emily Leproust Sells Shares

What Happened
Emily M. Leproust, CEO of Twist Bioscience (TWST), sold 2,423 shares on March 6, 2026 at $46.43 per share, generating gross proceeds of $112,490. The Form 4 lists the sale as an open-market/private sale (code S), but the filing’s footnote clarifies this was a mandated "sell-to-cover" to satisfy tax withholding on vested restricted stock units (RSUs), not a discretionary trade.

Key Details

  • Transaction date: March 6, 2026; Price: $46.43 per share; Shares sold: 2,423; Proceeds: $112,490.
  • Filing date (Form 4): March 10, 2026 — appears timely (filed within the required two business days).
  • Shares owned after transaction: not reported in this Form 4.
  • Notable footnote: F1 — sale was required to cover tax withholding on RSU vesting and did not represent a discretionary sale by the reporting person.
  • Transaction code: S (sale); footnote indicates the sale is for tax withholding (often reported as F in explanatory notes).

Context
Sell-to-cover transactions are routine administrative sales that occur when a company requires some vested shares to be sold to pay required taxes; they generally do not signal the insider’s view on the company. This filing only reports a tax-withholding sale tied to RSU vesting and does not indicate additional purchases, gifts, or option exercises by the CEO.

Insider Transaction Report

Form 4
Period: 2026-03-06
Leproust Emily M.
DirectorChief Executive Officer
Transactions
  • Sale

    Common Stock

    [F1]
    2026-03-06$46.43/sh2,423$112,490860,629 total
Holdings
  • Employee Stock Option (right to buy)

    [F2]
    Exercise: $5.95Exp: 2025-09-28Common Stock (0 underlying)
    0
  • Employee Stock Option (right to buy)

    [F3]
    Exercise: $8.82Exp: 2027-09-28Common Stock (0 underlying)
    150,879
  • Employee Stock Option (right to buy)

    [F4]
    Exercise: $26.66Exp: 2028-11-18Common Stock (0 underlying)
    266,539
  • Employee Stock Option (right to buy)

    [F5]
    Exercise: $23.33Exp: 2029-10-23Common Stock (0 underlying)
    131,290
  • Employee Stock Option (right to buy)

    [F6]
    Exercise: $67.85From: 2022-12-19Exp: 2030-08-31Common Stock (64,950 underlying)
    64,950
Footnotes (6)
  • [F1]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
  • [F2]The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  • [F3]The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  • [F4]20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  • [F5]25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  • [F6]Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Signature
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust|2026-03-10

Documents

1 file
  • 4
    marketforms-72430.xmlPrimary

    PRIMARY DOCUMENT